PPARG and glomerulosclerosis: Similarly, we and others have found that a combination of aldosterone synthase inhibitor and ARB, or a combination of proliferator-activated receptor γ (PPARγ) agonist and ARB, induced more regression of glomerulosclerosis than monotherapy in the 5/6 nephrectomy model [34].